Quetiapine in anorexia nervosa patients: An open label outpatient pilot study
Version of Record online: 22 AUG 2006
Copyright © 2006 Wiley Periodicals, Inc.
International Journal of Eating Disorders
Volume 40, Issue 1, pages 21–26, January 2007
How to Cite
Powers, P. S., Bannon, Y., Eubanks, R. and McCormick, T. (2007), Quetiapine in anorexia nervosa patients: An open label outpatient pilot study. Int. J. Eat. Disord., 40: 21–26. doi: 10.1002/eat.20325
- Issue online: 26 DEC 2006
- Version of Record online: 22 AUG 2006
- Manuscript Accepted: 18 MAY 2006
- anorexia nervosa;
The main objective of the study was to determine whether quetiapine was effective in reducing scores on the positive and negative syndrome scale (PANSS) in anorexia nervosa (AN) patients. Secondary objectives included determining whether quetiapine was effective in reducing symptoms of anxiety and depression. In addition, the effect on weight was determined.
In an open label design, 19 patients with AN but without schizophrenia or schizoaffective disorder were given 150–300 mg quetiapine daily over a 10 week period. Results were analyzed using last observation carried forward (LOCF).
Fourteen patients completed the study and all but one of the 5 patients who dropped out returned for an early termination visit. Scores on the total, general psychopathology, and depression scales of the PANSS declined significantly (p = .024, .010, .0005, respectively) at LOCF. There were improvements in several measures of anxiety, depression, and obsessive compulsive symptoms. Mean weight gain was modest at 1.6 lbs (0.73 kg). Adverse events were generally mild and no patients discontinued due to adverse events
Quetiapine was well-tolerated and patients had significant improvements in several subscales of the PANSS as well as decreases in measures of anxiety and depression. © 2006 by Wiley Periodicals, Inc. Int J Eat Disord 2006